IP Library Patent Application 12910237
Patent Application
App. No. 12/910,237

INJECTION OF FIBRIN SEALANT IN THE ABSENCE OF CORTICOSTEROIDS IN SPINAL APPLICATIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/910,237
Abstract

A method and kit for treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus. The method includes injecting a fibrin sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises fibrinogen and an activating compound, wherein at least a portion of the fibrin forms after injection, with the proviso that a corticosteroid is absent from the fibrin sealant injected into the disc.

Claims (22)

1 . A composition for forming a resorbable tissue scaffold for enhancing tissue repair of at least one fissure in the anulus fibrosus of a painful intervertebral disc comprising: fibrinogen, thrombin, and calcium chloride.

2 . The composition of claim 1 that includes a fibrinolysis inhibitor.

3 . The composition of claim 2 wherein the fibrinolysis inhibitor is aprotinin.

4 . The composition of claim 2 wherein the fibrinolysis inhibitor is aprotinin acetate.

5 . The composition of claim 2 wherein the scaffold is one of conductive and inductive.

6 . A method of enhancing tissue repair of at least one defect in the anulus fibrosus of an intervertebral disc comprising:

injecting fibrinogen, thrombin, calcium chloride, and aprotinin into a disc;

wherein (a) the fibrinogen and thrombin react to form a fibrin clot within at least a portion of at least one defect in the anulus fibrosus, (b) the fibrin clot includes a resorbable scaffold for tissue formation, and (c) the aprotinin downregulates the cellular synthesis of inflammatory cytokines and upregulates the syntheses of tissue growth factors to promote tissue repair.

7 . The method of claim 6 , wherein the aprotinin includes includes aprotinin acetate.

8 . The method of claim 6 , including injecting the fibrinogen, thrombin, calcium chloride, protein, and aprotinin into a soft tissue defect included in the disc.

9 . The method of claim 6 , including reduce cellular synthesis of inflammatory cytokines and proteolytic enzymes based on the aprotinin.

10 . The method of claim 6 , including injecting a metabolic agent that promote anabolic tissue formation.

11 . The method of claim 6 , including injecting a metabolic agent that stimulates cellular synthesis of anabolic growth factors.

12 . A method of enhancing tissue repair of at least one defect in the anulus fibrosus of an intervertebral disc comprising:

injecting fibrinogen, thrombin, calcium chloride, and a fibrinolysis inhibitor into a disc;

wherein (a) the fibrinogen and thrombin react to form a fibrin clot within at least a portion of at least one defect in the anulus fibrosus, (b) the fibrin clot includes a resorbable scaffold for tissue formation, (c) the fibrinolysis inhibitor downregulates the cellular synthesis of inflammatory cytokines and upregulates the syntheses of tissue growth factors to promote tissue repair.

13 . The method of claim 12 , wherein the fibrinolysis inhibitor includes one of aprotinin and aprotinin acetate.

14 . The method of claim 13 including forming a tissue matrix for enhancing repair within the at least one fissure in the anulus fibrosus.

15 . The method of claim 13 wherein the disc is degenerated and prone to rapid degredation from elevated concentrations of proteloytic enzymes and low pH present within the disc.

16 . The method of claim 12 , wherein the fibrinolysis inhibitor includes aprotinin, the fibrinogen is between 60 and 110 mg/mL, the thrombin is between 390 and 640 IU/mL, the Calcium Chloride is between 30 and 50 μmol/mL, and the Aprotinin is between 2200 and 3900 KIU/mL.

17 . The method of claim 12 , wherein the fibrinolysis inhibitor includes aprotinin configured to upregulate the syntheses of tissue growth factors for longer than 4 weeks after injection into the disc.

18 . The method of claim 12 , wherein the fibrinolysis inhibitor includes aprotinin configured to downregulate cellular synthesis of inflammatory cytokines for longer than 2 weeks after injection into the disc.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Aug 22, 2013
From: COMERICA BANK
To: SPINAL RESTORATION, INC.
Reel/Frame 031062/0653 →
SECURITY AGREEMENT Recorded Sep 6, 2012
From: SPINAL RESTORATION, INC.
To: COMERICA BANK
Reel/Frame 028918/0119 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2011
From: WHITLOCK, STEVEN I.; BURKINSHAW, BRIAN D; PAUZA, KEVIN; WHEELER, JOHN L.; THORNE, KEVIN
To: SPINAL RESTORATION, INC.
Reel/Frame 026271/0927 →